Sanofi-Aventis and Novalar file OraVerse in certain EU countries
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis and Novalar Pharmaceuticals have filed OraVerse (phentolamine mesylate) for the reversal of local anaesthesia for the acceleration for normal sensation and function following routine dental procedures in the UK, Germany, Italy, France and Spain.